套细胞淋巴瘤的一线治疗管理
套细胞淋巴瘤(MCL)仍大多不可治愈,复发/难治(R/R)疾病治疗选择有限且缓解持续时间短,因此提高一线(1L)治疗疗效、最大化首次缓解持续时间对获得良好长期结局至关重要。本文综述支持当前标准治疗的数据,探讨1L管理可能推进的6个主要领域,并强调可能很快影响一线MCL管理的进行中3期试验。
要点
- MCL仍大多不可治愈,提高1L疗效和首次缓解持续时间对长期结局至关重要。
- 靶向药物已是R/R MCL治疗支柱,正在一线治疗中建立改变范式的新角色。
- 1L管理可能推进的6个领域包括优化CIT backbone、CIT联合靶向药物、重新定义ASCT角色、改进维持治疗、靶向药物联合省略CIT、MRD指导治疗。
核心结论
- 尽管近期治疗进展众多,MCL仍大多不可治愈;提高1L治疗疗效、最大化首次缓解持续时间对获得良好长期结局至关重要。
- 随着1L治疗更有效,改善耐受性也正成为日益现实的目标。
- 靶向药物已在R/R MCL中成为治疗支柱,并正在一线治疗中建立新的、改变范式的角色。
研究设计与样本
- 综述,回顾支持当前标准治疗的数据,并探讨1L管理可能推进的6个主要领域。
主要发现
- R/R MCL治疗选择数量有限且缓解持续时间有限。
- 靶向药物已是R/R MCL治疗支柱,并正在一线治疗中建立新角色。
- 若干进行中的3期试验可能很快影响一线MCL管理。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite many recent therapeutic advances, mantle cell lymphoma (MCL) remains a largely incurable disease. Treatments for patients with relapsed/refractory (R/R) disease are limited in number and in response durability. Therefore, improving the efficacy of frontline (1L) treatment, and specifically maximizing the duration of first remission, remains of critical importance to obtain favorable long-term outcomes. As 1L treatments become more effective, improving tolerability is also becoming an increasingly realistic goal. Targeted agents, which are now mainstays of treatment in R/R MCL, are establishing new, paradigm-changing roles in frontline treatment. Here, we review data supporting current standard-of-care approaches and explore 6 main areas of possible focus for advancement of 1L management: optimizing the chemoimmunotherapy (CIT) backbone, adding targeted agents to CIT, redefining the role of autologous stem cell transplantation, improving maintenance therapy, using targeted agent combinations with omission of CIT, and using measurable residual disease-guided therapy. We highlight several ongoing phase 3 trials that may soon impact frontline MCL management, and outline some areas of necessary investigation as the field continues to strive toward a cure for this disease.
引用
- Ryan CE, Armand P, LaCasce AS, et al. Frontline management of mantle cell lymphoma. Blood. 2025. PMID: 38498174. doi:10.1182/blood.2023022352
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。